<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">CardioSomatics</journal-id><journal-title-group><journal-title xml:lang="en">CardioSomatics</journal-title><trans-title-group xml:lang="ru"><trans-title>CardioСоматика</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2221-7185</issn><issn publication-format="electronic">2658-5707</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">569019</article-id><article-id pub-id-type="doi">10.17816/CS569019</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original study articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Associations of the rs1132896 polymorphism of the matrix metalloproteinase type 2 gene with the development of acute cerebrovascular accident: prospective case–control study</article-title><trans-title-group xml:lang="ru"><trans-title>Ассоциации полиморфизма rs1132896 гена матриксной металлопротеиназы 2-го типа с развитием острого нарушения мозгового кровообращения: проспективное исследование случай–контроль</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="spin">7122-4397</contrib-id><name-alternatives><name xml:lang="en"><surname>Nikulin</surname><given-names>Dmitrii A.</given-names></name><name xml:lang="ru"><surname>Никулин</surname><given-names>Дмитрий Александрович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Med.), assistant</p></bio><bio xml:lang="ru"><p>канд. мед. наук, ассистент</p></bio><email>nikulin86@list.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2977-1792</contrib-id><contrib-id contrib-id-type="spin">6094-7406</contrib-id><name-alternatives><name xml:lang="en"><surname>Chernova</surname><given-names>Anna A.</given-names></name><name xml:lang="ru"><surname>Чернова</surname><given-names>Анна Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>anechkachernova@yandex.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6968-7627</contrib-id><contrib-id contrib-id-type="spin">1789-3359</contrib-id><name-alternatives><name xml:lang="en"><surname>Nikulina</surname><given-names>Svetlana Yu.</given-names></name><name xml:lang="ru"><surname>Никулина</surname><given-names>Светлана Юрьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>nicoulina@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4778-2586</contrib-id><contrib-id contrib-id-type="spin">1279-7072</contrib-id><name-alternatives><name xml:lang="en"><surname>Prokopenko</surname><given-names>Semen V.</given-names></name><name xml:lang="ru"><surname>Прокопенко</surname><given-names>Семён Владимирович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>s.v.proc.58@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3825-3946</contrib-id><contrib-id contrib-id-type="spin">9715-1475</contrib-id><name-alternatives><name xml:lang="en"><surname>Cherkashina</surname><given-names>Irina I.</given-names></name><name xml:lang="ru"><surname>Черкашина</surname><given-names>Ирина Ивановна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Med.), Professor</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор</p></bio><email>cherkashina@list.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Voyno-Yasenetsky Krasnoyarsk State Medical University</institution></aff><aff><institution xml:lang="ru">Красноярский государственный медицинский университет им. проф. В.Ф. Войно-Ясенецкого</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Federal Siberian Scientific and Clinical Center</institution></aff><aff><institution xml:lang="ru">Федеральный Сибирский научно-клинический центр</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2023-11-13" publication-format="electronic"><day>13</day><month>11</month><year>2023</year></pub-date><pub-date date-type="pub" iso-8601-date="2023-12-20" publication-format="electronic"><day>20</day><month>12</month><year>2023</year></pub-date><volume>14</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>215</fpage><lpage>222</lpage><history><date date-type="received" iso-8601-date="2023-09-04"><day>04</day><month>09</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-10-11"><day>11</day><month>10</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, ООО "Эко-Вектор"</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">ООО "Эко-Вектор"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://cardiosomatics.ru/2221-7185/article/view/569019">https://cardiosomatics.ru/2221-7185/article/view/569019</self-uri><abstract xml:lang="en"><p><bold>BACKGROUND:</bold><italic> </italic>The study focused on the identification of new genetic predictors in the Russian population, particularly associations of the rs1132896 polymorphism of the matrix metalloproteinase type 2 gene (<italic>MMP-2</italic>) with the development of acute cerebrovascular accident (ACVA).</p> <p><bold>OBJECTIVE:</bold><italic> </italic>To investigate the relationship of rs1132896 gene <italic>MMP-2</italic> polymorphisms with ACVA development.</p> <p><bold>MATERIALS AND METHODS</bold><italic>: </italic>The prospective, case–control study enrolled 318 patients with stroke (main group) and 323 controls (control group). The age of the patients in the main group ranged from 32 to 69 [57.0; 51.0–62.0] years. In the control group, the age of the patients ranged from 37 to 68 [55.0; 51.0–62.0] years, which was comparable to that of the main group. Sexual dimorphism was as follows: 191 men (age [56.5; 51.0–62.0]) and 127 women (age [57.0; 51.0–62.0]). The sex composition in the control group corresponded to that in the main group: 214 men (age [55.0; 51.0–62.0]) and 109 women (age [55.0; 51.0–62.0]). The main group underwent clinical examination, computed tomography of the brain, electrocardiography, echocardioscopy, duplex ultrasound scanning of the extracranial brachiocephalic arteries, 24-h monitoring of blood pressure and heart rate, and analysis of the blood coagulation system. Molecular genetic research was conducted at a branch of the Institute of Cytology and Genetics of the Siberian Branch of RAS (Novosibirsk). All patients provided written informed consent to participate voluntarily in the study. The duration of the study was 3 years, starting in 2019. The primary study endpoint was a diagnosis of stroke, verification of concomitant cardiovascular pathology, and risk factors for stroke development. Statistical processing of the results was performed using SPSS Statistics v. 22 (IBM Corp., USA) and MedCalc 22.006 (Microsoft, USA). When comparing extended variables, the Mann–Whitney <italic>U</italic>-test was used. Discrete values were compared using Pearson’s χ<sup>2</sup> test.</p> <p><bold>RESULTS:</bold><italic> </italic>When analyzing statistical significance, a predominance of the homozygous CC genotype was recorded in the group of male patients with stroke: <italic>n=</italic>24 (12.6%) <italic>vs</italic> <italic>n=</italic>20 (9.3%; <italic>p=</italic>0.0324). In addition, in the group of women, a statistically significant predominance of the heterozygous CG genotype was noted in women with stroke: <italic>n=</italic>67 (52.8%) <italic>vs</italic> <italic>n=</italic>42 (38.5%; <italic>p=</italic>0.0420).</p> <p><bold>CONCLUSION:</bold><italic> </italic>The homozygous CC genotype in men and the heterozygous CG genotype in women may be genetic predictors of the development of ACVA. The study of genetic factors in the development of ACVA is necessary to create a personalized approach to patient management at the outpatient and inpatient stages of medical care.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование.</bold> Выявление в российской популяции новых генетических предикторов, в частности, ассоциаций полиморфизма rs1132896 гена матриксной металлопротеиназы 2-го типа (<italic>MMP-2</italic>) с развитием острого нарушения мозгового кровообращения (ОНМК), является актуальной задачей.</p> <p><bold>Цель. </bold>Изучить ассоциации полиморфизма rs1132896 гена <italic>MMP-2</italic> с развитием ОНМК.</p> <p><bold>Материалы и методы.</bold> Объектом проспективного исследования случай–контроль выступили 318 пациентов с ОНМК (основная группа) и 323 человека контрольной группы. Возраст пациентов основной группы составил от 32 до 69 лет [57,0; 51,0–62,0]. У пациентов контрольной группы возраст был сопоставим с таковым основной группы: от 37 до 68 лет [55,0; 51,0–62,0]. Половой диморфизм был следующим: 191 мужчина (возраст [56,5; 51,0–62,0]) и 127 женщин (возраст [57,0; 51,0–62,0]). Половой состав лиц контрольной группы соответствовал таковому основной группы: 214 мужчин (возраст [55,0; 51,0–62,0]) и 109 женщин (возраст [55,0; 51,0–62,0]). Всем пациентам основной группы проводили клинический осмотр, компьютерную томографию головного мозга, электрокардиографию, эхокардиоскопию, ультразвуковое дуплексное сканирование экстракраниальных брахиоцефальных артерий, суточное мониторирование артериального давления и сердечного ритма, анализ свертывающей системы крови. Молекулярно-генетическое исследование выполняли в филиале Института цитологии и генетики СО РАН (Новосибирск). Все пациенты подписали письменное добровольное информированное согласие на участие в исследовании. Продолжительность исследования составила 3 года, первичная конечная точка исследования — диагностика ОНМК у пациентов, верификация сопутствующей сердечно-сосудистой патологии и факторов риска развития ОНМК. Статистическую обработку результатов выполняли при помощи пакетов программ SPSS Statistics v. 22 (IBM, США), MedCalc 22.006 (Microsoft, США). При сравнении протяжённых переменных применяли <italic>U</italic>-критерий Манна–Уитни. Дискретные величины сравнивали с помощью критерия χ<sup>2</sup> Пирсона.</p> <p><bold>Результаты. </bold>При анализе статистической значимости зарегистрировано преобладание гомозиготного генотипа CC в группе больных мужчин с ОНМК: <italic>n=</italic>24 (12,6%) против <italic>n=</italic>20 (9,3%; <italic>p=</italic>0,0324). Кроме того, в группе женщин отмечено статистически значимое преобладание гетерозиготного генотипа CG у женщин с ОНМК: <italic>n=</italic>67 (52,8%) против <italic>n=</italic>42 (38,5%; <italic>p=</italic>0,0420).</p> <p><bold>Заключение.</bold> Гомозиготный генотип CC у мужчин и гетерозиготный генотип CG у женщин могут являться генетическими предикторами развития ОНМК. Изучение генетических факторов развития ОНМК необходимо для создания персонифицированного подхода к ведению пациента на амбулаторном и стационарном этапе оказания медицинской помощи.</p></trans-abstract><kwd-group xml:lang="en"><kwd>acute cerebrovascular accident</kwd><kwd>polymorphism</kwd><kwd>matrix metalloproteinase type 2 gene (MPP-2)</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>острое нарушение мозгового кровообращения</kwd><kwd>полиморфизм</kwd><kwd>ген матриксной металлопротеиназы 2-го типа (MMP-2)</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Niu F, Wei B, Yan M, et al. Matrix metalloproteinase-2 gene polymorphisms are associated with ischemic stroke in a Hainan population. Medicine (Baltimore). 2018;97(39):e12302. doi: 10.1097/MD.0000000000012302</mixed-citation><mixed-citation xml:lang="ru">Niu F., Wei B., Yan M., et al. Matrix metalloproteinase-2 gene polymorphisms are associated with ischemic stroke in a Hainan population // Medicine (Baltimore). 2018. Vol. 97, N 39. P. e12302. doi: 10.1097/MD.0000000000012302</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Lucivero V, Prontera M, Mezzapesa DM, et al. Different roles of matrix metalloproteinases-2 and -9 after human ischaemic stroke. Neurol Sci. 2007;28(4):165–170. doi: 10.1007/s10072-007-0814-0</mixed-citation><mixed-citation xml:lang="ru">Lucivero V., Prontera M., Mezzapesa D.M., et al. Different roles of matrix metalloproteinases-2 and -9 after human ischaemic stroke // Neurol Sci. 2007. Vol. 28, N 4. P. 165–170. doi: 10.1007/s10072-007-0814-0</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Galis ZS, Sukhova GK, Libby P. Microscopic localization of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue. FASEB J. 1995;9(10):974–980. doi: 10.1096/fasebj.9.10.7615167</mixed-citation><mixed-citation xml:lang="ru">Galis Z.S., Sukhova G.K., Libby P. Microscopic localization of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue // FASEB J. 1995. Vol. 9, N 10. P. 974–980. doi: 10.1096/fasebj.9.10.7615167</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Du J, Jin T, Cao Y, et al. Association between genetic polymorphisms of MMP8 and the risk of steroid-induced osteonecrosis of the femoral head in the population of northern China. Medicine (Baltimore). 2016;95(37):e4794. doi: 10.1097/MD.0000000000004794</mixed-citation><mixed-citation xml:lang="ru">Du J., Jin T., Cao Y., et al. Association between genetic polymorphisms of MMP8 and the risk of steroid-induced osteonecrosis of the femoral head in the population of northern China // Medicine (Baltimore). 2016. Vol. 95, N 37. P. e4794. doi: 10.1097/MD.0000000000004794</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Romanic AM, White RF, Arleth AJ, et al. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke. 1998;29(5):1020–1030. doi: 10.1161/01.str.29.5.1020</mixed-citation><mixed-citation xml:lang="ru">Romanic A.M., White R.F., Arleth A.J., et al. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size // Stroke. 1998. Vol. 29, N 5. P. 1020–1030. doi: 10.1161/01.str.29.5.1020</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Clark AW, Krekoski CA, Bou SS, et al. Increased gelatinase A (MMP-2) and gelatinase-B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett. 1997;238(1–2):53–56. doi: 10.1016/s0304-3940(97)00859-8</mixed-citation><mixed-citation xml:lang="ru">Clark A.W., Krekoski C.A., Bou S.S., et al. Increased gelatinase A (MMP-2) and gelatinase-B (MMP-9) activities in human brain after focal ischemia // Neurosci Lett. 1997. Vol. 238, N 1–2. P. 53–56. doi: 10.1016/s0304-3940(97)00859-8</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Mun-Bryce S, Rosenberg GA. Matrix metalloproteinases in cerebrovascular disease. J Cereb Blood Flow Metab. 1998;18(11):1163–1172. doi: 10.1097/00004647-199811000-00001</mixed-citation><mixed-citation xml:lang="ru">Mun-Bryce S., Rosenberg G.A. Matrix metalloproteinases in cerebrovascular disease // J Cereb Blood Flow Metab. 1998. Vol. 18, N 11. P. 1163–1172. doi: 10.1097/00004647-199811000-00001</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Fatar M, Stroick M, Griebe M, Hennerici M. Matrix metalloproteinases in cerebrovascular diseases. Cerebrovasc Dis. 2005;20(3):141–151. doi: 10.1159/000087197</mixed-citation><mixed-citation xml:lang="ru">Fatar M., Stroick M., Griebe M., Hennerici M. Matrix metalloproteinases in cerebrovascular diseases // Cerebrovasc Dis. 2005. Vol. 20, N 3. P. 141–151. doi: 10.1159/000087197</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Rosenberg GA, Navratil M. Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat. Neurology. 1997;48(4):921–926. doi: 10.1212/wnl.48.4.921</mixed-citation><mixed-citation xml:lang="ru">Rosenberg G.A., Navratil M. Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat // Neurology. 1997. Vol. 48, N 4. P. 921–926. doi: 10.1212/wnl.48.4.921</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Vecil GG, Larsen PH, Corley SM, et al. Interleukin-1 is a key regulator of matrix metalloproteinase-9 expression in human neurons in culture and following mouse brain trauma in vivo. J Neurosci Res. 2000;61(2):212–224. doi: 10.1002/1097-4547(20000715)61:2&lt;212::AID-JNR12&gt;3.0.CO;2-9</mixed-citation><mixed-citation xml:lang="ru">Vecil G.G., Larsen P.H., Corley S.M., et al. Interleukin-1 is a key regulator of matrix metalloproteinase-9 expression in human neurons in culture and following mouse brain trauma in vivo // J Neurosci Res. 2000. Vol. 61, N 2. P. 212–224. doi: 10.1002/1097-4547(20000715)61:2&lt;212::AID-JNR12&gt;3.0.CO;2-9</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Cunningham LA, Wetzel M, Rosenberg GA. Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia. 2005;50(4):329–339. doi: 10.1002/glia.20169</mixed-citation><mixed-citation xml:lang="ru">Cunningham L.A., Wetzel M., Rosenberg G.A. Multiple roles for MMPs and TIMPs in cerebral ischemia // Glia. 2005. Vol. 50, N 4. P. 329–339. doi: 10.1002/glia.20169</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Liu L, Sun J, Li G, et al. Association between MMP-12-82A/G polymorphism and cancer risk: a meta-analysis. Int J Clin Exp Med. 2015;8(8):11896–11904.</mixed-citation><mixed-citation xml:lang="ru">Liu L., Sun J., Li G., et al. Association between MMP-12-82A/G polymorphism and cancer risk: a meta-analysis // Int J Clin Exp Med. 2015. Vol. 8, N 8. P. 11896–11904.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Jia P, Wu N, Zhang X, Jia D. Association of matrix metalloproteinase-1-519A/G polymorphism with acute coronary syndrome: a meta-analysis. Int J Clin Exp Med. 2015;8(4):5675–5682.</mixed-citation><mixed-citation xml:lang="ru">Jia P., Wu N., Zhang X., Jia D. Association of matrix metalloproteinase-1-519A/G polymorphism with acute coronary syndrome: a meta-analysis // Int J Clin Exp Med. 2015. Vol. 8, N 4. P. 5675–5682.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Zhang Y, Wang M, Zhang S. Association of MMP-9 gene polymorphisms with glaucoma: a meta-analysis. Ophthalmic Res. 2016;55(4):172–179. doi: 10.1159/000443627</mixed-citation><mixed-citation xml:lang="ru">Zhang Y., Wang M., Zhang S. Association of MMP-9 gene polymorphisms with glaucoma: a meta-analysis // Ophthalmic Res. 2016. Vol. 55, N 4. P. 172–179. doi: 10.1159/000443627</mixed-citation></citation-alternatives></ref></ref-list></back></article>
